查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2103543

神經科學市場：全球市場預測，2026-2032年

Neuroscience Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，神經科學市場將成長至 341.5 億美元，複合年成長率為 10.69%。

主要市場統計數據
基準年 2025 167.7億美元
預計年份：2026年 186.1億美元
預測年份 2032 341.5億美元
複合年成長率 (%) 10.69%

神經科學融合了生物學、醫學、工程學、資料科學和行為健康等多個學科，是全球醫療保健和生命科學領域最具戰略意義的領域之一。此領域涵蓋腦圖譜繪製、神經退化性疾病研究、神經精神病學、神經影像學、神經調控、神經藥理學、神經遺傳學、認知神經科學、計算神經科學以及腦機介面的開發。阿茲海默症、帕金森氏症、癲癇、中風、偏頭痛、憂鬱症、泛自閉症障礙、創傷性腦憂鬱症、多發性硬化症和物質使用障礙等疾病日益加重的臨床和社會負擔，進一步推動了神經科學創新發展的需求。公共衛生領域的檢驗證據表明，神經系統疾病是全球殘疾的主要原因之一，而精神疾病和認知障礙則持續增加對長期照護的需求，對勞動生產力構成挑戰，並加重醫療保健系統的負擔。

此外，高解析度成像、單細胞分析、多體學、數位生物標記、穿戴式感測器、電生理學、非侵入性刺激、神經資訊學和人工智慧等分析技術的進步正在重塑神經科學領域。研究機構、醫院、公共組織和科技公司正日益將神經科學計畫與精準醫療、早期診斷、病​​患分層、個人化治療、復健和遠距監測相結合。決策者的機會並非取決於孤立的科學發現，而是取決於能否檢驗為臨床實用、符合倫理且可擴展的解決方案，涵蓋預防、診斷、治療和長期神經系統護理的各個方面。

神經科學領域的變革性變化

神經科學生態系統正經歷著一場結構性轉變，從基於症狀的評估轉向以機制主導、數據豐富且以患者為中心的照護模式。傳統的神經系統評估嚴重依賴病歷、身體檢查、結構影像學檢查和間歇性測試。雖然這些基礎仍然至關重要，但如今它們正被穿戴式裝置持續資料收集、數位化認知功能測試、言語和步態分析、遠端腦電圖以及先進的影像學方案所補充。這種轉變正在增強我們更早發現疾病進展、更客觀地監測治療反應以及支持分散式神經系統照護的能力。

人工智慧對神經科學的累積影響

人工智慧正透過加速發現、改進模式識別以及實現對複雜腦相關數據的更精確解讀，對神經科學產生累積和協同性的影響。在神經影像學領域，人工智慧技術正被用於支援分割、病灶檢測、體積分析、影像重建以及跨磁振造影（MRI）、電腦斷層掃描（CT）、正子斷層掃描（PET）和功能性影像的多模態整合。在電生理學領域，機器學習正在輔助訊號分類、癲癇發作檢測、睡眠分期分析以及神經活動模式的解讀。在神經退化性疾病的研究中，人工智慧正在整合影像學、遺傳學、蛋白質體學、臨床記錄、認知功能評估和數位生物標記物，以幫助識別疾病亞型和進展特徵。

神經科學領域的關鍵區域見解

在亞太地區，神經科學領域正憑藉著不斷擴展的醫院網路、日益精進的神經影像技術、國家級腦科學舉措以及對中風、失智症、癲癇和精神疾病解決方案的強勁需求而迅速發展。該地區各國正大力投資數位醫療基礎設施、大規模生物醫學研究和老化相關照護模式，同時都市區學術中心也加強其轉化神經科學能力。北美地區仍然是神經科學研究、監管科學、臨床試驗、先進神經技術、數位療法和精準神經病學領域的領先中心。該地區充分利用其在成熟的學術醫療中心、廣泛的生物醫學研究資助體系、先進影像技術的高普及率以及計算神經科學與臨床實踐的緊密結合等方面的優勢。

神經科學領域的關鍵團體見解

東協正崛起為神經科學的關鍵區域，面臨中風發病率高、人口老化導致失智症日益增加以及精神衛生服務持續存在差距等問題。同時，東協成員國正在推進全民健康覆蓋（UHC）計劃、建立數位醫療系統並擴展專科醫療體系。跨境合作、醫療旅遊中心和行動優先的醫療模式正在推動神經科學的應用，尤其是在都市區。海灣合作理事會（GCC）優先發展先進的醫療基礎設施、三級專科醫院、基因組醫學和數位轉型，為神經病學、神經復健和精神衛生保健的現代化以及人工智慧驅動的臨床工作流程奠定堅實基礎。該地區的人口結構變化和慢性病趨勢進一步凸顯了製定綜合腦健康策略的必要性。

主要國家神經科學的發展趨勢

美國在神經科學研究、精準神經病學、神經技術、先進成像、臨床試驗和人工智慧驅動的生物醫學分析領域處於世界領先地位，並在阿茲海默症、帕金森氏症、癲癇、中風、精神健康和腦機介面等領域進行積極研究。加拿大擁有強大的學術網路和公共衛生重點，在神經影像學、認知神經科學、精神健康研究、神經倫理學和人群健康方面提供關鍵專業知識。墨西哥正透過擴大神經系統疾病照護、精神健康計畫、中風管理和學術研究來提升神經科學的重要性，儘管醫療保健資源分配不均仍然是實施過程中的挑戰。巴西憑藉其龐大的人口、完善的公共衛生體系、在神經傳染病感染疾病的經驗、對失智症和癲癇治療的關注以及數位醫療的日益普及，正在大力推進大規模的神經科學計劃。

為神經科學領域的領導者提供的實用建議

行業領導者應優先考慮經臨床檢驗的神經科學解決方案，以提高治療的可及性、可負擔性和患者療效，同時應對棘手的神經和精神疾病。最有效的策略是將神經科學研究融入實際臨床工作流程，確保數位生物標記、人工智慧工具、影像分析、神經調控系統和療法都有透明的證據、代表性的數據和可衡量的效用作為支撐。領導者應投資建立可互通的數據平台，將影像、電生理、基因組學、實驗室數據、認知功能測試、患者報告結果和縱向臨床記錄連接起來，同時保持強力的隱私和網路安全措施。

神經調查方法及其獲取洞見的途徑

本執行摘要採用基於檢驗的公共領域和機構認可的證據來源的二手研究途徑編寫而成。分析內容包括同行評審的神經科學文獻、公共衛生出版物、臨床指南、監管文件、學術研究成果、疾病負擔研究、數位健康政策文件以及來自認證醫療和公共衛生組織的科學報告。調查方法強調跨多個證據類別的三角檢驗，包括流行病學趨勢、技術應用模式、臨床工作流程的變化、監管方向以及區域醫療保健系統優先事項。

關於神經科學未來的結論

神經科學正邁入一個新時代，其特點是精準的腦健康管理、整合的數據生態系統、人工智慧、先進的神經技術以及從發現到醫療應用的更完善的轉化路徑。這一領域不再局限於實驗室研究或神經病學專科實踐；它正成為全球應對老化、心理健康、慢性病管理、減輕殘疾和提升人類機能策略的核心。神經和精神疾病負擔的日益加重，使得早期發現、個人化治療、復健和長期監測成為全球醫療保健系統的當務之急。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 神經科學市場：依產品類型分類

  • 醫療設備
    • 醫療影像設備
      • 電腦斷層掃描（CT）掃描儀
      • 腦電圖（EEG）測量設備
      • 磁振造影（MRI）
    • 監控設備
      • 侵入式監測設備
      • 非侵入式監測設備
    • 治療設備
      • 神經控制裝置
      • 復健設備
  • 服務
    • 諮詢服務
    • 維護服務
  • 軟體
    • 分析軟體
    • 視覺化軟體

第8章 神經科學市場：依技術分類

  • 電腦斷層掃描（CT）
  • 腦電圖（EEG）
  • 功能性近紅外線光譜
  • 磁振造影
  • 磁腦電圖

第9章：神經科學市場：依應用領域分類

  • 診斷
    • 心血管疾病
    • 神經病變
    • 腫瘤影像
  • 監測
  • 調查
  • 治療方法
    • 神經調控
    • 復健治療

第10章 神經科學市場：依最終用戶分類

  • 診所
  • 醫院
  • 製藥公司
  • 研究機構

第11章 神經科學市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 神經科學市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 神經科學市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Blackrock Neurotech
  • DeepMind Technologies
  • Eli Lilly and Company
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Neurocrine Biosciences, Inc.
  • NeuroPace
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd
Product Code: MRR-C002B1C9955F

The Neuroscience Market is projected to grow by USD 34.15 billion at a CAGR of 10.69% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.77 billion
Estimated Year [2026] USD 18.61 billion
Forecast Year [2032] USD 34.15 billion
CAGR (%) 10.69%

Neuroscience sits at the intersection of biology, medicine, engineering, data science, and behavioral health, making it one of the most strategically important fields in global healthcare and life sciences. The discipline spans brain mapping, neurodegenerative disease research, neuropsychiatry, neuroimaging, neuromodulation, neuropharmacology, neurogenetics, cognitive neuroscience, computational neuroscience, and brain-computer interface development. Demand for neuroscience innovation is being reinforced by the growing clinical and social burden of Alzheimer's disease, Parkinson's disease, epilepsy, stroke, migraine, depression, autism spectrum disorder, traumatic brain injury, multiple sclerosis, and substance use disorders. Verified public-health evidence shows that neurological conditions are among the leading causes of disability worldwide, while mental health and cognitive disorders continue to drive long-term care needs, workforce productivity challenges, and healthcare system pressure.

The neuroscience landscape is also being reshaped by advances in high-resolution imaging, single-cell analysis, multi-omics, digital biomarkers, wearable sensors, electrophysiology, non-invasive stimulation, neuroinformatics, and artificial intelligence-enabled analytics. Research institutions, hospitals, public agencies, and technology developers are increasingly aligning neuroscience programs with precision medicine, early diagnosis, patient stratification, personalized therapeutics, rehabilitation, and remote monitoring. For decision-makers, the opportunity is not defined by isolated scientific discovery but by the ability to translate validated neural insights into clinically useful, ethically governed, and scalable solutions across prevention, diagnosis, treatment, and long-term neurological care.

Transformative Shifts in the Neuroscience Landscape

The neuroscience ecosystem is undergoing a structural shift from symptom-based assessment toward mechanism-driven, data-rich, and patient-centered models of care. Traditional neurological evaluation has relied heavily on clinical history, physical examination, structural imaging, and episodic testing. These foundations remain essential, but they are now being augmented by continuous data capture from wearables, digital cognitive testing, speech and gait analytics, remote electroencephalography, and advanced imaging protocols. This transition is expanding the ability to detect disease progression earlier, monitor therapeutic response more objectively, and support decentralized neurological care.

Another major transformation is the convergence of neuroscience with immunology, genetics, and metabolic science. Neuroinflammation, protein misfolding, synaptic dysfunction, mitochondrial impairment, gut-brain signaling, and vascular contributions to cognitive impairment are receiving greater research attention. This is accelerating biomarker discovery and supporting more targeted therapeutic strategies for complex neurological and psychiatric disorders. At the same time, neurotechnology is moving from specialized research environments into clinical and consumer-adjacent settings through neuromodulation devices, rehabilitation robotics, immersive therapy platforms, and assistive brain-computer interfaces.

Regulatory and ethical expectations are also changing. Neuroscience solutions increasingly require evidence not only of analytical validity but also of clinical utility, safety, equity, interoperability, explainability, and data protection. Because brain data can be deeply sensitive and personally identifying, governance around consent, algorithmic bias, neuroprivacy, and responsible use is becoming central to adoption. Organizations that combine scientific rigor with transparent validation, multidisciplinary collaboration, and ethical deployment are best positioned to shape the next phase of neuroscience innovation.

Cumulative Impact of Artificial Intelligence on Neuroscience

Artificial intelligence is having a cumulative and compounding effect on neuroscience by accelerating discovery, improving pattern recognition, and enabling more precise interpretation of complex brain-related data. In neuroimaging, AI-supported methods are used to assist segmentation, lesion detection, volumetric analysis, image reconstruction, and multimodal integration across magnetic resonance imaging, computed tomography, positron emission tomography, and functional imaging. In electrophysiology, machine learning supports signal classification, seizure detection, sleep-stage analysis, and interpretation of neural activity patterns. In neurodegenerative disease research, AI is helping integrate imaging, genetics, proteomics, clinical records, cognitive assessments, and digital biomarkers to identify disease subtypes and progression signatures.

The impact extends beyond diagnostics. AI-enabled computational models are supporting drug discovery, target identification, molecular screening, patient selection, and trial enrichment in neurological and psychiatric disorders, where clinical heterogeneity has historically limited development success. Natural language processing is improving the extraction of neurological phenotypes from electronic health records and clinical notes, while predictive analytics can support care pathway optimization and earlier intervention. In rehabilitation and assistive technologies, AI is enhancing adaptive neuroprosthetics, personalized therapy programs, speech restoration tools, and closed-loop neuromodulation systems.

However, the value of AI in neuroscience depends on data quality, representative datasets, prospective validation, regulatory alignment, and clinical integration. Brain-related datasets often differ by scanner type, protocol, ethnicity, age, comorbidity profile, language, and socioeconomic context, creating risks of bias and reduced generalizability. Leaders must prioritize explainable models, human-in-the-loop workflows, federated learning where appropriate, secure data infrastructure, and independent validation across diverse populations. AI is not replacing neuroscience expertise; it is amplifying it by revealing patterns that are difficult to detect through conventional analytical methods alone.

Key Regional Insights in Neuroscience

Asia-Pacific is advancing rapidly in neuroscience through expanding hospital networks, increasing neuroimaging capacity, national brain science initiatives, and strong demand for solutions addressing stroke, dementia, epilepsy, and psychiatric disorders. Countries across the region are investing in digital health infrastructure, large-scale biomedical research, and aging-related care models, while urban academic centers are strengthening translational neuroscience capabilities. North America remains a major hub for neuroscience research, regulatory science, clinical trials, advanced neurotechnology, digital therapeutics, and precision neurology. The region benefits from mature academic medical centers, extensive biomedical funding ecosystems, high adoption of advanced imaging, and strong integration of computational neuroscience with clinical practice.

Latin America is seeing growing neuroscience relevance as health systems address stroke burden, mental health access gaps, epilepsy care, neuroinfectious disease impacts, and dementia preparedness. Regional progress is supported by public health initiatives, specialist training, and telemedicine adoption, although access to advanced diagnostics and specialty care remains uneven. Europe maintains a strong neuroscience base through coordinated research frameworks, population health data resources, cross-border clinical collaboration, and robust ethical governance for brain research and digital health. The region's focus on neurodegeneration, mental health, rehabilitation, and health data standards supports evidence-based adoption of neuroscience innovations.

The Middle East is strengthening neuroscience capacity through investments in tertiary hospitals, specialist neurology centers, medical education, and digital health modernization. Demand is shaped by noncommunicable disease trends, trauma-related neurological needs, and increasing recognition of mental health and neurodevelopmental conditions. Africa presents a highly important neuroscience landscape due to the combined burden of epilepsy, stroke, traumatic injury, infectious and post-infectious neurological complications, neurodevelopmental disorders, and limited specialist availability in many settings. Growth in tele-neurology, workforce training, community-based care, and scalable diagnostic tools is essential for improving neurological outcomes across the continent.

Key Group Insights in Neuroscience

ASEAN is emerging as a critical neuroscience region as member states expand universal health coverage efforts, digital health systems, and specialty care capacity while confronting high stroke incidence, dementia growth linked to population aging, and continuing gaps in mental health services. Cross-border collaboration, medical tourism hubs, and mobile-first care models are shaping neuroscience adoption, particularly in urban centers. The GCC is prioritizing advanced healthcare infrastructure, tertiary specialty hospitals, genomic medicine, and digital transformation, creating strong conditions for neurology, neurorehabilitation, mental health modernization, and AI-enabled clinical workflows. The region's demographic transition and chronic disease profile are reinforcing the need for integrated brain health strategies.

The European Union provides one of the most structured environments for neuroscience research and implementation, supported by harmonized regulatory expectations, public research programs, health data initiatives, and strong ethical oversight. Neuroscience activity in the EU emphasizes neurodegenerative disease, psychiatric research, neurotechnology governance, rehabilitation science, and cross-country evidence generation. BRICS economies represent a diverse and influential neuroscience bloc, combining large patient populations, expanding biomedical research capabilities, growing digital health adoption, and major public health needs related to stroke, dementia, epilepsy, neurodevelopmental disorders, and mental health. These countries are important for scalable, cost-effective, and population-specific neuroscience solutions.

The G7 countries play a central role in shaping global neuroscience standards through advanced research infrastructure, regulatory leadership, clinical trial networks, neuroimaging expertise, and investment in aging, dementia, mental health, and neurotechnology. Their priorities influence scientific norms for data quality, patient safety, and responsible AI use. NATO member countries also have distinct neuroscience relevance through research on traumatic brain injury, psychological resilience, neurorehabilitation, sleep, cognitive performance, blast exposure, and military-to-civilian translation of medical technologies. Across these groups, the strongest opportunities lie in interoperable data ecosystems, responsible AI, workforce development, and equitable access to neurological care.

Key Country Insights in Neuroscience

The United States is a global leader in neuroscience research, precision neurology, neurotechnology, advanced imaging, clinical trials, and AI-enabled biomedical analytics, with strong activity in Alzheimer's disease, Parkinson's disease, epilepsy, stroke, mental health, and brain-computer interface research. Canada contributes significant expertise in neuroimaging, cognitive neuroscience, mental health research, neuroethics, and population health, supported by strong academic networks and public health priorities. Mexico is strengthening neuroscience relevance through neurological care expansion, mental health initiatives, stroke management, and academic research, while access disparities continue to shape implementation needs. Brazil has a substantial neuroscience agenda driven by its large population, public health system, neuroinfectious disease experience, dementia concerns, epilepsy care, and growing digital health adoption.

The United Kingdom maintains a strong position in neuroscience through biomedical research infrastructure, national health data assets, dementia studies, psychiatric research, neuroimaging, and clinical translation. Germany is a key European neuroscience center with strengths in neurodegeneration, neuroengineering, medical devices, neuroimmunology, and high-quality hospital-based research. France contributes leading work in brain imaging, neurology, psychiatry, cognitive science, and neurotechnology governance, while maintaining a strong public research base. Russia has established traditions in neurophysiology, neurology, space medicine, and brain research, with current opportunities linked to clinical modernization and digital tools. Italy is active in neurorehabilitation, neurodegenerative disease, multiple sclerosis research, and aging-related brain health. Spain is increasingly visible in neuroscience through neuroimaging, mental health, neurodegeneration, stroke care, and collaborative European research programs.

China has rapidly expanded neuroscience capacity through national brain science programs, hospital development, AI research, neuroimaging, genomics, and high-volume clinical research addressing dementia, stroke, depression, and neurodevelopmental conditions. India is a high-priority neuroscience country due to its large neurological disease burden, expanding digital health infrastructure, growing specialist networks, and need for scalable diagnostics and mental health solutions. Japan's neuroscience priorities are strongly shaped by population aging, dementia research, robotics, neurorehabilitation, advanced imaging, and regenerative medicine. Australia contributes notable strengths in brain health, mental health, neurodegenerative disease, digital health, and rural telehealth models. South Korea is advancing neuroscience through strong biomedical technology capabilities, hospital innovation, neuroimaging, digital therapeutics, and research into dementia, stroke, and psychiatric disorders.

Actionable Recommendations for Neuroscience Leaders

Industry leaders should prioritize clinically validated neuroscience solutions that address high-burden neurological and psychiatric conditions while improving access, affordability, and patient outcomes. The most effective strategies will integrate neuroscience research with real-world clinical workflows, ensuring that digital biomarkers, AI tools, imaging analytics, neuromodulation systems, and therapeutics are supported by transparent evidence, representative data, and measurable utility. Leaders should invest in interoperable data platforms that connect imaging, electrophysiology, genomics, laboratory data, cognitive testing, patient-reported outcomes, and longitudinal clinical records while maintaining strong privacy and cybersecurity controls.

Organizations should build multidisciplinary teams that include neurologists, psychiatrists, neuroscientists, rehabilitation specialists, data scientists, engineers, ethicists, regulatory experts, and patient representatives. Early engagement with regulators, payers, clinicians, and care delivery organizations can reduce adoption barriers and improve evidence generation. For AI-enabled neuroscience applications, leaders should implement bias testing, model monitoring, explainability standards, and external validation across diverse demographic and clinical populations. For neurotechnology and brain-computer interface programs, neuroprivacy, informed consent, long-term safety, human autonomy, and equitable access should be embedded from design through deployment.

Commercial and institutional strategies should also focus on decentralized care, tele-neurology, remote monitoring, and scalable diagnostic pathways, particularly for regions with limited specialist availability. Partnerships with academic centers, hospitals, public health agencies, and patient advocacy groups can accelerate translation while strengthening trust. Leaders that align innovation with clinical need, ethical governance, and real-world usability will be best positioned to deliver durable impact in neuroscience.

Research Methodology for Neuroscience Insights

This executive summary is developed using a secondary research approach grounded in verified public-domain and institutionally recognized evidence sources. The analysis draws on peer-reviewed neuroscience literature, public health publications, clinical guideline resources, regulatory documents, academic research outputs, disease burden studies, digital health policy materials, and scientific reports from recognized medical and public health institutions. The methodology emphasizes triangulation across multiple evidence categories, including epidemiological trends, technology adoption patterns, clinical workflow evolution, regulatory direction, and regional health system priorities.

The research process focuses on qualitative synthesis rather than market sizing or forecasting. Key themes were identified by examining neurological and psychiatric disease burden, advancements in neuroimaging and neurotechnology, adoption of artificial intelligence in biomedical research and care delivery, data governance requirements, and translational barriers in clinical neuroscience. Regional, group, and country insights were assessed through healthcare infrastructure maturity, research ecosystem strength, demographic trends, neurological care needs, digital health readiness, and policy emphasis on brain health.

To maintain relevance and reliability, conclusions are restricted to data-backed and widely documented developments, avoiding speculative commercial claims. Emphasis is placed on practical implications for industry leaders, healthcare stakeholders, research organizations, and innovation teams operating across neuroscience, neurology, psychiatry, neurorehabilitation, and brain health technologies.

Conclusion on the Future of Neuroscience

Neuroscience is moving into a new era defined by precision brain health, integrated data ecosystems, artificial intelligence, advanced neurotechnology, and stronger translational pathways from discovery to care delivery. The field is no longer limited to laboratory investigation or specialist neurology practice; it is becoming central to global strategies for aging, mental health, chronic disease management, disability reduction, and human performance. The rising burden of neurological and psychiatric disorders makes early detection, personalized treatment, rehabilitation, and long-term monitoring urgent priorities for health systems worldwide.

The strongest momentum is occurring where scientific innovation aligns with validated clinical need, ethical data governance, and scalable implementation. AI, digital biomarkers, neuromodulation, neuroimaging, and computational neuroscience are expanding what is possible, but adoption will depend on trust, evidence, equity, and integration into real-world workflows. Regional and country-level differences in infrastructure, specialist availability, regulation, and disease burden will continue to shape how neuroscience solutions are developed and deployed.

For industry leaders, the path forward requires disciplined innovation: invest in robust evidence, design for interoperability, protect sensitive brain data, validate across diverse populations, and prioritize patient-centered outcomes. Organizations that combine scientific excellence with responsible technology deployment will play a defining role in improving brain health and advancing the future of neuroscience.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Neuroscience Market, by Product Type

  • 7.1. Introduction
  • 7.2. Devices
    • 7.2.1. Imaging Devices
      • 7.2.1.1. Computed Tomography Devices
      • 7.2.1.2. Electroencephalography Devices
      • 7.2.1.3. Magnetic Resonance Imaging Devices
    • 7.2.2. Monitoring Devices
      • 7.2.2.1. Invasive Monitoring Devices
      • 7.2.2.2. Non Invasive Monitoring Devices
    • 7.2.3. Therapeutic Devices
      • 7.2.3.1. Neuromodulation Devices
      • 7.2.3.2. Rehabilitation Devices
  • 7.3. Services
    • 7.3.1. Consultancy Services
    • 7.3.2. Maintenance Services
  • 7.4. Software
    • 7.4.1. Analysis Software
    • 7.4.2. Visualization Software

8. Neuroscience Market, by Technology

  • 8.1. Introduction
  • 8.2. Computed Tomography
  • 8.3. Electroencephalography
  • 8.4. Functional Near Infrared Spectroscopy
  • 8.5. Magnetic Resonance Imaging
  • 8.6. Magnetoencephalography

9. Neuroscience Market, by Application

  • 9.1. Introduction
  • 9.2. Diagnostics
    • 9.2.1. Cardiovascular Disorders
    • 9.2.2. Neurological Disorders
    • 9.2.3. Oncology Imaging
  • 9.3. Monitoring
  • 9.4. Research
  • 9.5. Therapy
    • 9.5.1. Neuromodulation
    • 9.5.2. Rehabilitation Therapy

10. Neuroscience Market, by End User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Hospitals
  • 10.4. Pharmaceutical Companies
  • 10.5. Research Institutes

11. Neuroscience Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Neuroscience Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Neuroscience Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. FPNV Positioning Matrix, 2025
  • 14.3. Market Concentration Analysis, 2025
    • 14.3.1. Concentration Ratio (CR)
    • 14.3.2. Herfindahl Hirschman Index (HHI)
  • 14.4. Recent Developments & Impact Analysis, 2025
  • 14.5. Product Portfolio Analysis, 2025
  • 14.6. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Abbott Laboratories
  • 15.2. AbbVie Inc.
  • 15.3. Amgen Inc.
  • 15.4. AstraZeneca PLC
  • 15.5. Biogen Inc.
  • 15.6. Blackrock Neurotech
  • 15.7. DeepMind Technologies
  • 15.8. Eli Lilly and Company
  • 15.9. Johnson & Johnson
  • 15.10. Merck & Co., Inc.
  • 15.11. Neurocrine Biosciences, Inc.
  • 15.12. NeuroPace
  • 15.13. Novartis AG
  • 15.14. Pfizer Inc.
  • 15.15. Roche Holding AG
  • 15.16. Sanofi S.A.
  • 15.17. Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROSCIENCE MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL NEUROSCIENCE MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL NEUROSCIENCE MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL NEUROSCIENCE MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL NEUROSCIENCE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEUROSCIENCE MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL NEUROSCIENCE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NEUROSCIENCE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL NEUROSCIENCE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NEUROSCIENCE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL NEUROSCIENCE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL NEUROSCIENCE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 21. GLOBAL NEUROSCIENCE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL NEUROSCIENCE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL NEUROSCIENCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMAGING DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMAGING DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMAGING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COMPUTED TOMOGRAPHY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPUTED TOMOGRAPHY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COMPUTED TOMOGRAPHY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ELECTROENCEPHALOGRAPHY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ELECTROENCEPHALOGRAPHY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ELECTROENCEPHALOGRAPHY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MAGNETIC RESONANCE IMAGING DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MAGNETIC RESONANCE IMAGING DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MAGNETIC RESONANCE IMAGING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MONITORING DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MONITORING DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INVASIVE MONITORING DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INVASIVE MONITORING DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INVASIVE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NON INVASIVE MONITORING DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NON INVASIVE MONITORING DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NON INVASIVE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL THERAPEUTIC DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL THERAPEUTIC DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL REHABILITATION DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL REHABILITATION DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL REHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CONSULTANCY SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CONSULTANCY SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CONSULTANCY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MAINTENANCE SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MAINTENANCE SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MAINTENANCE SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANALYSIS SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANALYSIS SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANALYSIS SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VISUALIZATION SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VISUALIZATION SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VISUALIZATION SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ELECTROENCEPHALOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ELECTROENCEPHALOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ELECTROENCEPHALOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FUNCTIONAL NEAR INFRARED SPECTROSCOPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FUNCTIONAL NEAR INFRARED SPECTROSCOPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FUNCTIONAL NEAR INFRARED SPECTROSCOPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MAGNETOENCEPHALOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MAGNETOENCEPHALOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MAGNETOENCEPHALOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIOVASCULAR DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CARDIOVASCULAR DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIOVASCULAR DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ONCOLOGY IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ONCOLOGY IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONCOLOGY IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEUROMODULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL REHABILITATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL REHABILITATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL REHABILITATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEUROSCIENCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE NEUROSCIENCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA NEUROSCIENCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEUROSCIENCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN NEUROSCIENCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. GCC NEUROSCIENCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. GCC NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. GCC NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 208. GCC NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 209. GCC NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 210. GCC NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 211. GCC NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 212. GCC NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 213. GCC NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. GCC NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. GCC NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 216. GCC NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. GCC NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS NEUROSCIENCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. G7 NEUROSCIENCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 245. G7 NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. G7 NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 247. G7 NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 248. G7 NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 249. G7 NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 250. G7 NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 251. G7 NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 252. G7 NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. G7 NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. G7 NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 255. G7 NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 256. G7 NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. NATO NEUROSCIENCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 258. NATO NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. NATO NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 260. NATO NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 261. NATO NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 262. NATO NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 263. NATO NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 264. NATO NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 265. NATO NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. NATO NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. NATO NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 268. NATO NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 269. NATO NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES NEUROSCIENCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. CANADA NEUROSCIENCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 285. CANADA NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. CANADA NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 287. CANADA NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 288. CANADA NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 289. CANADA NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 290. CANADA NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 291. CANADA NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 292. CANADA NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 293. CANADA NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 294. CANADA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 295. CANADA NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 296. CANADA NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. MEXICO NEUROSCIENCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 298. MEXICO NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. MEXICO NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 300. MEXICO NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 301. MEXICO NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 302. MEXICO NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 303. MEXICO NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 304. MEXICO NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 305. MEXICO NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 306. MEXICO NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 307. MEXICO NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 308. MEXICO NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 309. MEXICO NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 310. BRAZIL NEUROSCIENCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 311. BRAZIL NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. BRAZIL NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 313. BRAZIL NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 314. BRAZIL NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 315. BRAZIL NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 316. BRAZIL NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 317. BRAZIL NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 318. BRAZIL NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 319. BRAZIL NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 320. BRAZIL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 321. BRAZIL NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 322. BRAZIL NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED KINGDOM NEUROSCIENCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED KINGDOM NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED KINGDOM NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED KINGDOM NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED KINGDOM NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED KINGDOM NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED KINGDOM NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED KINGDOM NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED KINGDOM NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED KINGDOM NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 333. UNITED KINGDOM NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 334. UNITED KINGDOM NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 335. UNITED KINGDOM NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 336. GERMANY NEUROSCIENCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 337. GERMANY NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 338. GERMANY NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 339. GERMANY NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 340. GERMANY NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 341. GERMANY NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 342. GERMANY NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 343. GERMANY NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 344. GERMANY NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 345. GERMANY NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 346. GERMANY NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 347. GERMANY NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 348. GERMANY NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 349. FRANCE NEUROSCIENCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 350. FRANCE NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 351. FRANCE NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 352. FRANCE NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 353. FRANCE NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 354. FRANCE NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 355. FRANCE NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 356. FRANCE NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 357. FRANCE NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 358. FRANCE NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 359. FRANCE NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 360. FRANCE NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 361. FRANCE NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 362. RUSSIA NEUROSCIENCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 363. RUSSIA NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 364. RUSSIA NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 365. RUSSIA NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 366. RUSSIA NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 367. RUSSIA NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 368. RUSSIA NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 369. RUSSIA NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 370. RUSSIA NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 371. RUSSIA NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 372. RUSSIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 373. RUSSIA NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 374. RUSSIA NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 375. ITALY NEUROSCIENCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 376. ITALY NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 377. ITALY NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 378. ITALY NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 379. ITALY NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 380. ITALY NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 381. ITALY NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 382. ITALY NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 383. ITALY NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 384. ITALY NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 385. ITALY NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 386. ITALY NEUROSCIENCE MARKET SIZE, BY TH